Key Points
-
Telomerase is an important drug target for cancer. It is expressed in most tumours from virtually all types of cancers and is required for long-term maintenance of telomeres, which in turn is crucial for the long-term survival of tumour cells.
-
Telomerase is a relatively specific cancer target as normal body cells express little or no telomerase for most of their lifespan and generally have longer telomeres than those in tumour cells.
-
Two major approaches to killing telomerase-positive tumour cells are in clinical trials. A direct telomerase inhibitor, GRN163L, is in trials in chronic lymphocytic leukaemia, multiple myeloma, solid tumours and non-small-cell lung cancer. Several therapeutic vaccines directed against the crucial telomerase protein TERT are in or have completed trials in leukaemia and renal, prostate, lung, skin, pancreatic and breast cancer.
-
Telomerase inhibitors can have fast-acting single-agent activity in certain cancers with short telomeres and rapid turnover, but this should not be the expectation in most patients.
-
Putative cancer stem cells are telomerase-positive and thus telomerase inhibitors, in combination with effective tumour de-bulking agents, might help meet a major unmet need: durability of response.
-
Telomerase vaccines offer the potential to stimulate the rapid killing of tumour cells by enhancing the activity of telomerase-specific cytotoxic (CD8+) and/or helper (CD4+) T cells. No significant toxicity to normal tissues has been seen in any of animal studies or clinical trials to date.
-
Potential challenges in the clinical development of telomerase-based cancer therapies include selection of the best patient population, good pharmacodynamic or biological markers to assess early activity, and optimal dose and schedule for combination therapies.
Abstract
Telomerase is an attractive cancer target as it appears to be required in essentially all tumours for immortalization of a subset of cells, including cancer stem cells. Moreover, differences in telomerase expression, telomere length and cell kinetics between normal and tumour tissues suggest that targeting telomerase would be relatively safe. Clinical trials are ongoing with a potent and specific telomerase inhibitor, GRN163L, and with several versions of telomerase therapeutic vaccines. The prospect of adding telomerase-based therapies to the growing list of new anticancer products is promising, but what are the advantages and limitations of different approaches, and which patients are the most likely to respond?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hanahan, J. D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Harley, C. B. et al. Telomerase, cell immortality, and cancer. Cold Spring Harbor Symp. Quant. Biol. 59, 307–315 (1994).
Hahn, W. C. et al. Inhibition of telomerase limits the growth of human cancer cells. Nature Med. 5, 1164–1170 (1999).
Kelland, L. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin. Cancer Res. 13, 4960–4963 (2007).
Greider, C. W. & Blackburn, E. H. Identification of a specific telomere terminal transferase enzyme with two kinds of primer specificity. Cell 51, 405–413 (1985). The discovery of the biochemical activity of telomerase is reported in a protozoan, enabling future work on the role of telomeres and telomerase in human ageing and cancer.
Greider, C. W. & Blackburn, E. H. A telomeric sequence in the RNA of tetrahymena telomerase required for telomere repeat synthesis. Nature 337, 331–337 (1989).
Liu, D., O'Connor, M. S., Qin, J. & Songyang, Z. Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins. J. Biol. Chem. 279, 51338–51342 (2004).
de Lange, T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19, 2100–2110 (2005). In this and the preceding reference, the collection of telomere-binding proteins is put into an emerging structure for the chromosome tip, the 'telosome' or 'shelterin', and potential interactions with telomerase are summarized.
Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458–460 (1990). The association between telomere loss and replicative ageing in normal human somatic cells is first reported.
Hastie, N. D. et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346, 866–868 (1990). The first broad survey of telomere lengths in pre-malignant and malignant tumour samples finds short telomeres in malignant cancer tissue.
Wellinger, R. J., Ethier, K., Labrecque, P. & Zakian, V. A. Evidence for a new step in telomere maintenance. Cell 16, 3094–3105 (1996).
Jacob, N. K., Kirk, K. E. & Price, C. M. Generation of telomeric G strand overhangs involves both G and C strand cleavage. Mol. Cell 11, 1021–1032 (2003).
Goldkorn, A. & Blackburn, E. H. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res. 66, 5763–5771 (2006).
Wright, W. E., Piatyszek, M. A., Rainey, W. E., Byrd, W. & Shay, J. W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18, 173–179 (1996).
Ulaner, G. A., Hu, J.-F., Vu, T. H., Giudice, L. C. & Hoffman, A. R. Telomerase activity in human development is regulated both by hTERT transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58, 4168–4172 (1998).
Kakuo, S., Asaoka, K. & Ide, T. Human is a unique species among primates in terms of telomere length. Biochem. Biophys. Res. Comm. 263, 308–314 (1999).
Steinert, S., White, D., Zou, Y., Shay, J. W. & Wright, W. E. Telomere biology and cellular aging in non-human primate cells. Exp. Cell Res. 272, 146–152 (2002).
Okuda, K. et al. Telomere length in the newborn. Pediatr. Res. 52, 377–381 (2002).
Bodnar, A., Kim, N. W., Effros, R. B. & Chiu, C.-P. Mechanism of telomerase induction during T cell activation. Exp. Cell Res. 228, 58–64 (1996).
Broccoli, D., Young, J. W. & de Lange, T. Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl Acad. Sci. 92, 9082–9086 (1995).
Chiu, C. P. et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 14, 239–248 (1996).
Harley, C. B. Telomere loss: mitotic clock or genetic time bomb? Mut. Res. 256, 271–282 (1991).
Counter, C. M. et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921–1929 (1992). Critically shortened telomeres in a model of cell transformation and immortalization are shown to be linked to genetic rearrangements that are stabilized when telomerase is activated.
Greenberg, R. A. et al. Short dysfunctional telomeres impair tumorigenesis in the INK4aD2/3 cancer-prone mouse. Cell 97, 515–525 (1999).
Hanahan, D. Benefits of bad telomeres. Nature 406, 573–574 (2000).
Harley, C. B. Telomerase is not an oncogene. Oncogene 21, 494–502 (2002).
Khoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H. & DePinho, R. A. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc. Natl Acad. Sci. USA 104, 3931–3936 (2007).
Cawthon, R. M., Smith, K. R., O'Brien, E., Sivatchenko, A. & Kerber, R. A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361, 359–395 (2003). A simple and rapid telomere length assay developed by the lead author is used in a human epidemiology study, demonstrating increased mortality risk of cancer in individuals with short telomeres.
Epel, E. S. et al. Accelerated telomere shortening in response to life stress. Proc. Natl Acad. Sci. 101, 17312–17315 (2004).
Benetos, A. et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 43, 182–185 (2004).
Vulliamy, T. et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nature Genet. 36, 447–449 (2004).
Walne, A., Marrone, A. & Dokal, I. Dyskeratosis congenita: a disorder of defective telomere maintenance? Int. J. Hematol. 82, 184–189 (2005).
Demissle, S. et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell 5, 325–330 (2006).
Fitzpatrick, A. L. et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am. J. Epidemiol. 165, 14–21 (2007).
Brouilette, S. W. et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369, 107–114 (2007).
Armanios, M. Y. et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356, 1370–1372 (2007).
Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011–2014 (1994). A highly sensitive PCR assay for telomerase activity (TRAP) is reported, enabling detection of telomerase in a broad range of tumour cell lines and in certain normal cells.
Shay, J. W. & Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787–791 (1997).
Keith, W. N., Bilsland, A., Hardie, M. & Evans, T. R. Drug Insight: cancer cell immortality — telomerase as a target for novel cancer gene therapies. Nat. Clin. Pract. Oncol. 1, 88–96 (2004).
Zimmermann, S. & Martens, U. M. Telomeres and telomerase as targets for cancer therapy Cell. Mol. Life Sci. 64 906–921 (2007).
Phatak, P. & Burger, A. M. Telomerase and its potential for therapeutic intervention. Br. J. Pharmacol. (2007).
Finkel, T., S. M. & Blasco, M. A. The common biology of cancer and ageing. Nature 448, 767–774 (2007).
Blasco, M. A. Telomere length, stem cells and aging. Nature Chem. Biol. 3, 640–649 (2007).
Greider, C. W. Telomeres, telomerase and senescence. BioEssays 12, 363–368 (1990).
Feng, J. et al. The RNA component of human telomerase. Science 269, 1236–1241 (1995). The RNA component of human telomerase is cloned and characterized, enabling specific modulation of telomerase activity and facilitating the discovery of telomerase inhibitors targeting the RNA template region of telomerase.
Nakamura, T. M. et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955–959 (1997). The catalytic protein component of human telomerase (TERT) is cloned, enabling further experimental manipulation of telomerase in normal and tumour tissues, and the development of the first telomerase-based drugs (TERT vaccines) to enter clinical trials.
Meyerson, M. et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785–795 (1997).
Harrington, L. et al. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 11, 3109–3115 (1997).
Weinrich, S. L. et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nature Genet. 17, 498–502 (1997).
Kilian, A. et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6, 2011–2019 (1997).
Nakayama, J.-I. et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nature Genet. 18, 65–68 (1998).
Cortez-Gonzalez, X. & Zanetti, M. Telomerase immunity from bench to bedside: round one. J. Transl. Med. 5, 12 (2007).
Fakhoury, J., Nimmo, G. A. & Autexier, C. Harnessing telomerase in cancer therapeutics. Anticancer Agents Med. Chem. 7, 475–483 (2007).
Hiyama, E. & Hiyama, K. Telomerase as tumor marker. Cancer Lett. 194, 221–233 (2003).
Armanios, M. & Greider, C. W. Telomerase and cancer stem cells. Cold Spring Harb. Symp. Quant. Biol. 70, 205–208 (2005).
Ho, M. M., Nq, A. V., Lam, S. & Hung., J. Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827–4833 (2007).
Phatak, P. et al. Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br. J. Cancer 96, 1223–1233 (2007).
Camp, E. R. et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin. Cancer Res. 11, 397–405 (2005).
Bilsland, A. E. et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22, 370–380 (2003). In vivo proof of concept using a prodrug suicide gene approach driven by either the hTR or the TERT promoter in a non-oncolytic adenoviral vector.
Zhang, Q. et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin. Cancer Res. 12, 6523–6531 (2006).
Irving, J. et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 11, 174–185 (2004). In vivo proof of concept and demonstration of safety for a conditional replicative oncolytic virus driven by the TERT promoter.
Li, S., Crothers, J., Haqq, C. M. & Blackburn, E. H. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J. Biol. Chem. 280, 23709–23717 (2005).
Xu, L. & Blackburn, E. H. Human cancer cells harbor T-stumps, a distinct class of extremely short telomeres. Mol. Cell. 28, 315–327 (2007).
Haider, S. M., Parkinson, G. N. & Neidle, S. Structure of a G-quadruplex-ligand complex. J. Mol. Biol. 326, 117–125 (2003).
Patel, D., Phan, A. & Kuryavyi, V. Human telomere, oncogenic promoter and 5′-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucl. Acids Res. 35, 7429–7455 (2007).
Gowan, S. et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol. Pharmacol. 61, 1154–1162 (2002).
Gunaratnam, M. et al. Mechanism of acridine-based telomerase inhibition and telomere shortening. Biochem. Pharmacol. 74, 679–689 (2007).
Salvati, E. et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J. Clin. Invest. 117, 3236–3247 (2007). In vivo proof of concept for a late preclinical drug candidate targeting the telomere.
Oganesian, L. & Bryan, T. Physiological relevance of telomeric G-quadruplex formation: a potential drug target. Bioessays 29, 155–165 (2007).
Pascolo, E. et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 277, 15566–15572 (2002).
Ward, R. J. & Autexier, C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol. Pharmacol. 68, 779–786 (2005).
Barma, D. K., Elayadi, A., Falck, J. R. & Corey, D. R. Inhibition of telomerase by BIBR 1532 and related analogues. Bioorg. Med. Chem. Lett. 13, 1333–1336 (2003).
Piotrowska, K. et al. Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors. Lab. Invest. 85, 1565–1569 (2005). Care must be taken in using the standard PCR-based TRAP assay for evaluation of telomerase inhibitors.
Zhou, S. et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med. 7, 1028–1034 (2001).
Asai, A. et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 63, 3931–3939 (2003).
Herbert, B. et al. Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24, 5262–5268 (2005). GRN163L, a telomerase inhibitor now in clinical trials, is demonstrated to have significantly enhanced cellular activity compared with its non-lipidated parent compound, GRN163.
Dikmen, Z. G. et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 65, 1–8 (2005).
Jackson, D. A. et al. Antiadhesive effects of GRN163L – an oligonucleotide N3′→P5′ thio-phosphoramidate targeting telomerase. Cancer Res. 67, 1121–1129 (2007).
Gellert, G. C., Dikmen, Z. G., Wright, W. E., Gryaznov, S. & Shay, J. W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 1–9 (2005).
Hochreiter, A. E. et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin. Cancer Res. 12, 3184–3192 (2006).
Gomez-Millan, J., Goldblatt, E. M., Gryaznov, S. M., Mendonca, M. S. & Herbert, B. S. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 67, 897–905 (2007). A representative report illustrating the telomere length-dependent activity of GRN163L in certain tumours, and synergy of telomerase inhibition and radiation in models of breast cancer.
Djojosubroto, M. W. et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42, 1–12 (2005).
Ozawa, T. et al. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro Oncol. 6, 218–226 (2004).
Dikmen, Z. G., Wright, W. E., Shay, J. W. & Gryaznov, S. M. Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells. J. Cell Biochem. (2007).
Akiyama, M. et al. Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63, 6187–6194 (2003).
Wang, E. S. et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103, 258–266 (2004).
Nair, N. K. et al. Induction of cytotoxic T cells responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature Med. 6, 1011–1013 (2000).
Vonderheide, R. et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 61, 8366–8370 (2001).
Cohen, S. B. et al. Protein composition of catalytically active human telomerase from immortal cells. Science 315, 1850–1853 (2007). The first report of a substantially pure form of human telomerase and the essential protein components associated with telomerase activity in a cell-free system.
Gannage, M. et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol. 174, 8210–8218 (2005).
Filaci, G. et al. Frequency of telomerase-specific CD8+ T lymphocytes in cancer patients. Blood 107, 1505–1512 (2005).
Nava-Parada, P. & Emens, L. A. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. Curr. Opin. Mol. Ther. 9, 490–497 (2007). The immulogical and apparent clinical responses with GV1001, a telomerase peptide vaccine now in phase II and III studies, are reported.
Brunsvig, P. F. et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 55, 1553–1564 (2006).
Su, Z. et al. Enhanced induction of telomerase-specific CD4+ T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 62, 5041–5048 (2002).
Dikmen, Z. et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 7866–7873 (2005).
Vonderheide, R. H. et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. 10, 828–839 (2004).
Su, Z. et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 174, 3798–3807 (2005). Strong immunological responses and signs of apparent clinical activity associated with immune responses are reported in prostate cancer patients given autologous TERT mRNA-transfected dendritic cell vaccines.
Mavroudis, D. et al. A phase I study of the optimized cryptic peptide TERT572Y in patients with advanced malignancies. Oncology 70, 306–314 (2006).
Parkhurst, M. R. et al. Immunization of patients with the hTERT:540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res. 10, 4688–4698 (2004).
Domchek, S. M. et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 67, 10546–10555 (2007). Induction of TERT-specific tumour-infiltrating cytotoxic T cells is associated with apparent signs of clinical activity with a TERT peptide vaccine, and patients with induced immune responses had longer median survival than those without induced immune responses.
Ramirez, R. D., Wright, W. E., Shay, J. W. & Taylor, R. S. Implications of telomerase activity in human hair follicles. J. Invest. Dermatol. 108, 113–117 (1997).
Danet-Desnoyers, G. A., Luongo, J. L., Bonnet, D. A., Domchek, S. M. & Vonderheide, R. H. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp. Hematol. 33, 1275–1280 (2005).
Hultdin, M. et al. Association between telomere length and VH gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br. J. Cancer 88, 593–598 (2003).
Damle, R. N. et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 103, 375–382 (2004).
Counter, C. M., Hirte, H. W., Bacchetti, S. & Harley, C. B. Telomerase activity in human ovarian carcinoma. Proc. Natl Acad. Sci. USA 91, 2900–2904 (1994). The first demonstration of specific telomerase expression in human tumour biopsy samples.
Saretzki, G., Ludwig, A., von Zglinicki, T. & Runnebaum, I. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 8, 827–834 (2001).
Jiang, F., Bao, J., Li, P., Nicosia, S. V. & Bai, W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation. J. Biol. Chem. 279, 53213–53221 (2004).
Roth, A. et al. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia 21, 2456–2462 (2007).
Wong, K.-K. et al. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nature Genet. 26, 85–88 (2000).
Tacken, P. J., de Vries, J. M., Torensma, R. & Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Rev. Immunol. 7, 790–802 (2007).
Effros, R. B. Telomerase induction in T cells: A cure for aging and disease? Exp. Gerontol. 42, 416–420 (2007).
Goronzy, J. J. et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol. 75, 12182–12187 (2001).
Ostergaard, M., Olesen, L. H., Hasle, H. & Hokland, K. E. WT1 gene expression: An excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukemia patients — results from a single centre study. Br. J. Haematol. 125, 590–600 (2004).
Roth, A. et al. Telomerase levels control the lifespan of human T lymphocytes. Blood 102, 849–857 (2003).
Vaziri, H. et al. Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age. Proc. Natl Acad. Sci. USA 91, 9857–9860 (1994).
Engelhardt, M. et al. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 12, 13–24 (1998).
Ricca, I. et al. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF. Leukemia 19, 644–651 (2005).
Thornley, I. et al. Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood 99, 2387–2396 (2002).
Franco, S. et al. Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia 17, 401–410 (2003).
Harley, C. B. Telomerase therapeutics for degenerative diseases. Curr. Mol. Med. 5, 205–211 (2005).
Zhong, Z. H. et al. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J. Biol. Chem. 282, 29314–29322 (2007).
Chang, S., Khoo, C. M., Naylor, M. L., Maser, R. S. & DePinho, R. A. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev. 17, 88–100 (2003).
Unryn, B., Cook, L. & Riabowol, K. Paternal age is positively linked to telomere length of children. Aging Cell 4, 97–101 (2005).
Njajou, O. T. et al. Telomere length is paternally inherited and is associated with parental lifespan. Proc. Natl Acad. Sci. USA 104, 12135–12139 (2007).
Ulaner, G. A. & Giudice, L. C. Developmental regulation of telomerase activity in human fetal tissues during gestation. Mol. Hum. Reprod. 3, 769–773 (1997).
Xu, J. & Yang, X. Telomerase activity in bovine embryos during early development. Biol. Reprod. 63, 1124–1128 (2000).
Schaetzlein, S. et al. Telomere length is reset during early mammalian embryogenesis. Proc. Natl Acad. Sci. USA 101, 8034–8038 (2004).
d' Adda di Fagagna, D. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194–198 (2003).
Karlseder, J., Smogorzewska, A. & de Lange, T. Senescence induced by altered telomere state, not telomere loss. Science 295, 2446–2449 (2002).
Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W. & Harley, C. B. Telomere end-replication problem and cell aging. J. Mol. Biol. 225, 951–960 (1992).
Baerlocher, G. M., Vulto, I., de Jong, G. & Lansdorp, P. M. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nature Protoc. 1, 2365–2376 (2006).
van Steensel, B. & de Lange, T. Control of telomere length by the human telomeric protein TRF1. Nature 385, 740–743 (1997).
Teixeira, M. T., Arneric, M., Sperisen, P. & Lingner, J. Telomere length homeostasis is achieved via a switch between telomerase- extendible and -nonextendible states. Cell 117, 323–335 (2004).
Ouellette, M. et al. Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J. Biol. Chem. 275, 10072–10076 (2000).
Liu, Y., Kha, H., Ungrin, M., Robinson, M. O. & Harrington, L. Preferential maintenance of critically short telomeres in mammalian cells heterozygous for mTert. Proc. Natl Acad. Sci. USA 99, 3597–3602 (2002).
Hug, N. & Lingner, J. Telomere length homeostasis. Chromosoma 115, 413–425 (2006).
Wallweber, G., Gryaznov, S., Pongracz, K. & Pruzan, R. Interaction of human telomerase with its primer substrate. Biochemistry 42, 589–600 (2003). Analysis of human telomerase primer binding and dissociation kinetics enabled characterization of the mechanism of action of template antagonist telomerase inhibitor GRN163L.
Hemann, M., Strong, M., Hao, L. & Greider, C. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107, 67–77 (2001).
Baird, D. M. Telomere dynamics in human cells. Biochimie 90, 116–121 (2008).
Mitchell, J. R., Cheng, J. & Collins, K. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3′ end. Mol. Cell. Biol. 19, 567–576 (1999).
Bernhardt, S. L. et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br. J. Cancer 95, 1474–1482 (2006).
Bolonaki, I. et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol. 25, 2727–2734 (2007).
Millard, F. E., Gerloni, M., Derrah, D., Farness, P. & Zanetti, M. Phase I study of transgenic B lymphocyte immunization (TLI) against telomerase in androgen-independent prostate cancer (PC). J. Clin. Oncol. 22, 2459 (2004).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Calvin B. Harley is a shareholder, employee and officer with Geron Corporation.
Related links
Related links
DATABASES
National Cancer Institute
National Cancer Institute Drug Dictionary
FURTHER INFORMATION
Glossary
- Replicative senescence
-
Cell-cycle arrest after a characteristic number of cell divisions (the 'Hayflick limit'), typically triggered by a DNA damage checkpoint associated with one or more dysfunctional telomeres.
- Crisis
-
A cellular state characterized by massive genomic instability and a high probability of cell death due to critically short telomeres.
- Cancer stem cell
-
An immortal cancer cell with self-renewing capacity and the ability to create or sustain a tumour cell population. For some tumour types, relatively non-stringent assays have been used to identify putative cancer stem cells.
- Therapeutic window
-
The range of doses or window of time in which a drug is therapeutically active without being unacceptably toxic.
- Suicide genes
-
Genes that, when actively expressed, lead to death of the cells. Expression of suicide genes is controlled by promoters (genetic regulators) that are preferentially activated in tumour cells (for example, telomerase promoters). Examples are genes that encode proteins that control replication of oncolytic viruses or enzymes that convert a prodrug into a toxic substance.
- Ribonucleoprotein
-
An association of protein and RNA. Telomerase is an example of a ribonucleoprotein with a specific enzymatic activity.
- G-quadruplex
-
A four-stranded nucleic acid structure stabilized by non-Watson–Crick base-pairing within stacks of four planar-orientated guanosine nucleotides. G-quadruplex structures can form within or between G-rich strands of telomeric DNA.
- Major histocompatibility complex (MHC) class I and class II
-
The MHC genes encode proteins that process and bind antigens (peptide fragments from self or non-self proteins). The antigen-binding proteins reside on the cell surface and present antigens to the T-cell receptor on T cells. Class I MHC-encoded proteins are expressed on all nucleated cells (including tumour cells and antigen-presenting cells) and display their antigen to cytotoxic T cells by binding CD8. Class II MHC-encoded proteins are expressed on specialized antigen-presenting cells, which present their antigen to T-helper cells by binding CD4.
- Human leukocyte antigen
-
(HLA). HLA genes are part of the major histocompatibility complex and encode the proteins that bind and present antigens to T cells.
- Antigen-presenting cell
-
Cells such as dendritic cells, macrophages and B cells that inherently express both major histocompatibility complex class I and class II genes and present antigen to T cells.
- Prostate-specific antigen velocity
-
The rate of increase in levels of prostate-specific antigen circulating in plasma.
- Granulocyte–macrophage colony-stimulating factor
-
A growth factor that stimulates production and migration of granulocytes and monocytes.
- Phenotypic lag
-
The delay between the initiation of telomere loss by telomerase inhibition and the arrest of cell proliferation owing to a dysfunctional telomere.
- Alternative lengthening of telomeres
-
(ALT). A recombination pathway for telomere maintenance observed in some telomerase-negative cells (in vitro and in vivo).
Rights and permissions
About this article
Cite this article
Harley, C. Telomerase and cancer therapeutics. Nat Rev Cancer 8, 167–179 (2008). https://doi.org/10.1038/nrc2275
Issue Date:
DOI: https://doi.org/10.1038/nrc2275
This article is cited by
-
The hTERT-p50 homodimer inhibits PLEKHA7 expression to promote gastric cancer invasion and metastasis
Oncogene (2023)
-
New Approaches to Myelodysplastic Syndrome Treatment
Current Treatment Options in Oncology (2022)
-
Human telomerase reverse transcriptase (hTERT) synergistic with Sp1 upregulate Gli1 expression and increase gastric cancer invasion and metastasis
Journal of Molecular Histology (2021)
-
HnRNP F/H associate with hTERC and telomerase holoenzyme to modulate telomerase function and promote cell proliferation
Cell Death & Differentiation (2020)
-
Human telomerase reverse transcriptase positively regulates mitophagy by inhibiting the processing and cytoplasmic release of mitochondrial PINK1
Cell Death & Disease (2020)